WEBVTT 1 00:00:00.630 --> 00:00:03.270 JELMYTO Instructions for Administration 2 00:00:03.270 --> 00:00:05.883 for pyelocalyceal instillation only. 3 00:00:07.050 --> 00:00:09.840 Please see accompanying Full Prescribing Information, 4 00:00:09.840 --> 00:00:11.370 Instructions for Pharmacy, 5 00:00:11.370 --> 00:00:13.413 and Instructions for Administration. 6 00:00:14.400 --> 00:00:17.250 Read and follow this Instructions for Administration 7 00:00:17.250 --> 00:00:20.940 prior to each JELMYTO instillation. 8 00:00:20.940 --> 00:00:22.740 This video contains information 9 00:00:22.740 --> 00:00:24.360 on how to instill JELMYTO 10 00:00:24.360 --> 00:00:27.150 using the reconstituted JELMYTO vial 11 00:00:27.150 --> 00:00:29.220 which you received from the pharmacy 12 00:00:29.220 --> 00:00:31.800 and the devices listed under supplies needed 13 00:00:31.800 --> 00:00:33.273 obtained by your facility. 14 00:00:35.250 --> 00:00:39.120 JELMYTO, mitomycin, for pyelocalyceal solution 15 00:00:39.120 --> 00:00:41.460 is indicated for the treatment of adult patients 16 00:00:41.460 --> 00:00:46.460 with low-grade upper tract urothelial cancer, LG-UTUC. 17 00:00:46.470 --> 00:00:48.450 The most common adverse reactions 18 00:00:48.450 --> 00:00:51.120 in greater than or equal to 20% of patients 19 00:00:51.120 --> 00:00:55.440 treated with JELMYTO were ureteric obstruction, flank pain, 20 00:00:55.440 --> 00:00:59.700 urinary tract infection, hematuria, abdominal pain, 21 00:00:59.700 --> 00:01:04.653 fatigue, renal dysfunction, nausea, dysuria, and vomiting. 22 00:01:05.970 --> 00:01:07.920 Important information you need to know 23 00:01:07.920 --> 00:01:09.753 before instilling JELMYTO. 24 00:01:10.860 --> 00:01:14.310 JELMYTO must be reconstituted by a healthcare professional 25 00:01:14.310 --> 00:01:16.320 prior to instillation. 26 00:01:16.320 --> 00:01:20.103 Reconstituted JELMYTO will appear as a semisolid gel. 27 00:01:21.030 --> 00:01:23.190 Once chilled, JELMYTO will convert 28 00:01:23.190 --> 00:01:25.353 to a viscous liquid for instillation. 29 00:01:26.910 --> 00:01:30.900 Once instilled into the patient's pyelocalyceal system, 30 00:01:30.900 --> 00:01:33.330 JELMYTO will fill and conform to the cavity 31 00:01:33.330 --> 00:01:34.890 and become a gel, 32 00:01:34.890 --> 00:01:37.530 thereby, exposing the tissue to mitomycin 33 00:01:37.530 --> 00:01:39.423 over a prolonged period of time. 34 00:01:41.100 --> 00:01:42.750 JELMYTO is viscous, 35 00:01:42.750 --> 00:01:45.630 even when it is a liquid in a chilled state. 36 00:01:45.630 --> 00:01:48.630 Therefore, you will need a Uroject12 Syringe Lever 37 00:01:48.630 --> 00:01:51.003 to instill JELMYTO into the patient. 38 00:01:52.410 --> 00:01:56.313 You cannot instill JELMYTO without the Urojet12 device. 39 00:01:58.530 --> 00:02:02.190 Instill as soon as possible after reconstitution. 40 00:02:02.190 --> 00:02:06.060 Store reconstituted JELMYTO at 68 degrees Fahrenheit 41 00:02:06.060 --> 00:02:08.160 to 77 degrees Fahrenheit, 42 00:02:08.160 --> 00:02:11.280 or 20 degrees Celsius to 25 degrees Celsius 43 00:02:11.280 --> 00:02:13.923 for up to 96 hours or four days. 44 00:02:16.380 --> 00:02:17.733 Protect from light. 45 00:02:19.950 --> 00:02:22.653 When ready to instill, chill JELMYTO 46 00:02:22.653 --> 00:02:26.790 to 27 degrees Fahrenheit to 41 degrees Fahrenheit 47 00:02:26.790 --> 00:02:30.360 or -3 degrees Celsius to 5 degrees Celsius 48 00:02:30.360 --> 00:02:34.080 for at least 10 minutes, but no longer than one hour 49 00:02:34.080 --> 00:02:36.390 to revert it to a liquid form. 50 00:02:36.390 --> 00:02:38.370 See the steps A through E 51 00:02:38.370 --> 00:02:41.340 for complete administration instructions. 52 00:02:41.340 --> 00:02:44.760 JELMYTO is a cytotoxic anti-cancer drug. 53 00:02:44.760 --> 00:02:46.590 Procedures for proper handling 54 00:02:46.590 --> 00:02:50.670 and disposal of anti-cancer drugs should be followed. 55 00:02:50.670 --> 00:02:51.963 Supplies needed. 56 00:02:53.550 --> 00:02:56.340 To instill JELMYTO, you will need one vial 57 00:02:56.340 --> 00:02:59.940 of reconstituted JELMYTO with a resultant concentration 58 00:02:59.940 --> 00:03:02.970 of four milligrams of mitomycin per milliliter 59 00:03:02.970 --> 00:03:04.830 following reconstitution. 60 00:03:04.830 --> 00:03:08.010 This will be prepared and provided by the pharmacy. 61 00:03:08.010 --> 00:03:11.010 You will also need the following ancillary supplies 62 00:03:11.010 --> 00:03:13.860 which will be provided by your facility. 63 00:03:13.860 --> 00:03:16.593 Do not substitute any of these components. 64 00:03:17.970 --> 00:03:19.830 TEVADAPTOR Syringe Adaptor 65 00:03:19.830 --> 00:03:23.190 or OnGuard 2 CSTD Syringe Adaptor, 66 00:03:23.190 --> 00:03:28.190 MEDALLION COP, or MEDALLION Luer Lock syringe 20 milliliter, 67 00:03:28.770 --> 00:03:31.890 ureteral catheter with molded Luer Lock port 68 00:03:31.890 --> 00:03:33.933 5-French or 7-French. 69 00:03:34.950 --> 00:03:37.113 Urojet12 Syringe Lever. 70 00:03:39.540 --> 00:03:40.440 Note. 71 00:03:40.440 --> 00:03:44.160 The Urojet12 Syringe Lever is a multi-use device 72 00:03:44.160 --> 00:03:47.433 and must be sterilized or disinfected before use. 73 00:03:48.300 --> 00:03:50.160 Please follow the sterilization 74 00:03:50.160 --> 00:03:52.650 or disinfection instructions detailed 75 00:03:52.650 --> 00:03:56.970 in the Uroject12 Syringe Lever Instructions for Use. 76 00:03:56.970 --> 00:03:59.880 An ice bath to chill the vial of JELMYTO 77 00:03:59.880 --> 00:04:02.280 prior to instillation. 78 00:04:02.280 --> 00:04:05.313 Section A: Measure the kidney volume. 79 00:04:07.200 --> 00:04:09.390 The instillation volume will be equal 80 00:04:09.390 --> 00:04:11.220 to the patient's kidney volume 81 00:04:11.220 --> 00:04:14.910 or 15 milliliters, whichever is lower. 82 00:04:14.910 --> 00:04:19.200 If the kidney volume is already known, proceed to section B. 83 00:04:19.200 --> 00:04:21.390 If the kidney volume is not known 84 00:04:21.390 --> 00:04:25.260 or needs to be reassessed, use the following steps. 85 00:04:25.260 --> 00:04:29.670 Perform a retrograde pyelogram using diluted contrast 86 00:04:29.670 --> 00:04:33.690 so that the entire renal pelvis and calyces are observed 87 00:04:33.690 --> 00:04:35.520 and contrast starts to flow 88 00:04:35.520 --> 00:04:38.733 below the ureteropelvic junction or UPJ. 89 00:04:39.930 --> 00:04:43.473 Record the volume of contrast injected at this point. 90 00:04:44.430 --> 00:04:47.400 Allow the contrast to drain from the kidney. 91 00:04:47.400 --> 00:04:50.490 This may take about five minutes. 92 00:04:50.490 --> 00:04:51.330 Note. 93 00:04:51.330 --> 00:04:54.573 Do not withdraw contrast back into the syringe. 94 00:04:55.890 --> 00:04:58.050 Repeat steps one through three 95 00:04:58.050 --> 00:05:01.080 two more times for a total of three measurements 96 00:05:01.080 --> 00:05:03.390 to improve accuracy. 97 00:05:03.390 --> 00:05:05.670 Average the three volume measurements 98 00:05:05.670 --> 00:05:08.250 and round to the nearest whole number. 99 00:05:08.250 --> 00:05:10.473 This is the patient's kidney volume. 100 00:05:12.000 --> 00:05:15.453 Section B: Select the Instillation Volume. 101 00:05:16.890 --> 00:05:20.070 Select the kidney volume or 15 milliliters, 102 00:05:20.070 --> 00:05:23.163 whichever is lower, as the instillation volume. 103 00:05:24.060 --> 00:05:24.893 Note. 104 00:05:24.893 --> 00:05:28.113 Maximum instillation volume is 15 milliliters. 105 00:05:29.700 --> 00:05:32.463 Record this volume for future instillations. 106 00:05:33.600 --> 00:05:36.243 Section C: Chill the JELMYTO. 107 00:05:38.850 --> 00:05:41.400 Place the JELMYTO vial in the ice bath 108 00:05:41.400 --> 00:05:45.300 for at least 10 minutes, but no longer than one hour. 109 00:05:45.300 --> 00:05:47.040 After at least 10 minutes 110 00:05:47.040 --> 00:05:50.130 advance the ureteral catheter over the guidewire 111 00:05:50.130 --> 00:05:54.510 towards the target anatomy in the pyelocalyceal system. 112 00:05:54.510 --> 00:05:58.233 Section D: Prepare the administration syringe. 113 00:05:59.370 --> 00:06:02.010 Once the vial is removed from the ice bath, 114 00:06:02.010 --> 00:06:04.230 you have four minutes to draw JELMYTO 115 00:06:04.230 --> 00:06:07.950 into the administration syringe before it solidifies. 116 00:06:07.950 --> 00:06:11.190 After four minutes, recap and place the components 117 00:06:11.190 --> 00:06:14.370 back in the ice bath for no more than 15 minutes 118 00:06:14.370 --> 00:06:16.830 to liquify the JELMYTO. 119 00:06:16.830 --> 00:06:18.390 Remove the JELMYTO vial 120 00:06:18.390 --> 00:06:20.553 from the ice bath and dry it off. 121 00:06:21.720 --> 00:06:23.490 Swirl the vial upright 122 00:06:23.490 --> 00:06:26.670 to ensure the JELMYTO is uniformly mixed. 123 00:06:26.670 --> 00:06:28.320 Connect the syringe adaptor 124 00:06:28.320 --> 00:06:31.233 to the 20 milliliter Luer Lock syringe. 125 00:06:32.070 --> 00:06:34.473 This will be the administration syringe. 126 00:06:35.880 --> 00:06:36.930 Slowly withdraw 127 00:06:36.930 --> 00:06:39.840 the calculated instillation volume of JELMYTO 128 00:06:39.840 --> 00:06:41.943 into the administration syringe. 129 00:06:42.870 --> 00:06:45.580 Press the clutch button on the Uroject12 130 00:06:47.790 --> 00:06:49.083 and pull the knob out. 131 00:06:51.030 --> 00:06:53.070 Insert the administration syringe 132 00:06:53.070 --> 00:06:55.450 into the Uroject12 Syringe Lever 133 00:06:56.340 --> 00:06:59.523 and rotate it clockwise until it locks in place. 134 00:07:00.720 --> 00:07:03.450 While pressing the clutch button, advance the lever 135 00:07:03.450 --> 00:07:06.723 to just above the administration syringe's plunger. 136 00:07:08.010 --> 00:07:10.710 Immediately proceed with the instillation steps 137 00:07:10.710 --> 00:07:14.820 in Section E to avoid JELMYTO solidification. 138 00:07:14.820 --> 00:07:17.433 Section E: Instill JELMYTO. 139 00:07:20.370 --> 00:07:24.123 Remove the syringe adaptor from the administration syringe. 140 00:07:25.530 --> 00:07:26.400 Note. 141 00:07:26.400 --> 00:07:28.860 If JELMYTO gets onto the syringe tip 142 00:07:28.860 --> 00:07:31.560 or the catheter's Luer Lock port, 143 00:07:31.560 --> 00:07:34.230 wipe it off immediately with sterile gauze 144 00:07:34.230 --> 00:07:38.280 so it does not solidify and prevent a secure connection. 145 00:07:38.280 --> 00:07:40.530 Refer to Frequently Asked Questions 146 00:07:40.530 --> 00:07:44.103 on the Instructions for Administration for further details. 147 00:07:45.180 --> 00:07:47.250 Connect the administration syringe 148 00:07:47.250 --> 00:07:50.370 to the ureteral catheter's Luer Lock port 149 00:07:50.370 --> 00:07:52.503 by rotating the syringe only. 150 00:07:53.400 --> 00:07:56.670 Using fluoroscopy, ensure the ureteral catheter 151 00:07:56.670 --> 00:07:59.193 is in the desired anatomical position. 152 00:08:00.030 --> 00:08:03.150 Gradually instill the JELMYTO into the patient 153 00:08:03.150 --> 00:08:04.320 by turning the knob 154 00:08:04.320 --> 00:08:07.680 at a rate of one to two seconds per stroke. 155 00:08:07.680 --> 00:08:11.163 The entire syringe must be emptied within one minute. 156 00:08:12.360 --> 00:08:15.663 Remove the ureteral catheter from the urinary tract. 157 00:08:17.580 --> 00:08:21.150 Remove the administration syringe from the Uroject12 158 00:08:21.150 --> 00:08:24.780 by rotating the syringe barrel counterclockwise. 159 00:08:24.780 --> 00:08:27.210 Discard the administration ancillaries 160 00:08:27.210 --> 00:08:30.780 according to your facility's disposal procedures. 161 00:08:30.780 --> 00:08:33.690 Send the Uroject12 to be reprocessed 162 00:08:33.690 --> 00:08:36.030 according to your facility's procedures 163 00:08:36.030 --> 00:08:40.560 and the Uroject12 Syringe Lever Instructions for Use. 164 00:08:40.560 --> 00:08:42.513 Frequently Asked Questions. 165 00:08:46.920 --> 00:08:49.233 How do I connect the syringe adaptor? 166 00:08:50.070 --> 00:08:53.070 Screw the Luer Lock end of the syringe adaptor 167 00:08:53.070 --> 00:08:56.193 onto the syringe hub until it is finger tight. 168 00:08:57.150 --> 00:09:00.960 How do I connect the syringe adaptor to the vial adaptor? 169 00:09:00.960 --> 00:09:02.550 Place the syringe adaptor 170 00:09:02.550 --> 00:09:05.340 over the vial adaptor and align the tabs, 171 00:09:05.340 --> 00:09:06.900 then press down firmly. 172 00:09:06.900 --> 00:09:09.993 You will hear a snap which confirms successful attachment. 173 00:09:11.100 --> 00:09:13.170 How do I disconnect the syringe adaptor 174 00:09:13.170 --> 00:09:14.760 from the vial adaptor? 175 00:09:14.760 --> 00:09:16.950 Pinch the tabs on the syringe adaptor 176 00:09:16.950 --> 00:09:19.143 to separate it from the vial adaptor. 177 00:09:22.590 --> 00:09:25.950 I am having a hard time working with reconstituted JELMYTO. 178 00:09:25.950 --> 00:09:27.663 It seems to be solidifying. 179 00:09:29.040 --> 00:09:32.730 If you are having difficulty pushing or withdrawing JELMYTO, 180 00:09:32.730 --> 00:09:36.000 recap and place the components back into the ice bath 181 00:09:36.000 --> 00:09:37.863 until JELMYTO liquifies. 182 00:09:39.240 --> 00:09:41.700 What should I do if there is JELMYTO spillage 183 00:09:41.700 --> 00:09:43.083 from the syringe tip? 184 00:09:44.280 --> 00:09:47.400 You will need to clean JELMYTO off the syringe tip 185 00:09:47.400 --> 00:09:49.680 and the Luer Lock port of the catheter 186 00:09:49.680 --> 00:09:53.190 to ensure the two components can connect securely. 187 00:09:53.190 --> 00:09:55.080 To clean the syringe tip, 188 00:09:55.080 --> 00:09:58.170 fold a sterile gauze pad in half twice, 189 00:09:58.170 --> 00:10:01.200 and push it into the inside of the Luer Lock port 190 00:10:01.200 --> 00:10:03.843 to wipe any JELMYTO off the threads. 191 00:10:05.610 --> 00:10:08.460 To clean the Luer Lock port on the catheter, 192 00:10:08.460 --> 00:10:12.510 use a sterile gauze pad to wipe off any JELMYTO. 193 00:10:12.510 --> 00:10:15.060 Verify that the connectors are clean to ensure 194 00:10:15.060 --> 00:10:18.363 a secure connection between the syringe and the catheter. 195 00:10:20.160 --> 00:10:22.320 Remember, the contents of this video 196 00:10:22.320 --> 00:10:25.560 do not replace the Full Prescribing Information. 197 00:10:25.560 --> 00:10:28.620 Please see accompanying Full Prescribing Information, 198 00:10:28.620 --> 00:10:30.300 Instructions for Pharmacy, 199 00:10:30.300 --> 00:10:32.433 and Instructions for Administration. 200 00:10:35.010 --> 00:10:36.900 Indications and usage. 201 00:10:36.900 --> 00:10:40.710 JELMYTO, mitomycin, for pyelocalyceal solution 202 00:10:40.710 --> 00:10:43.320 is indicated for the treatment of adult patients 203 00:10:43.320 --> 00:10:47.463 with low-grade upper tract urothelial cancer, LG-UTUC. 204 00:10:48.720 --> 00:10:51.090 Important safety information. 205 00:10:51.090 --> 00:10:52.623 Contraindications. 206 00:10:53.820 --> 00:10:56.190 JELMYTO is contraindicated in patients 207 00:10:56.190 --> 00:11:00.240 with perforation of the bladder or upper urinary tract, 208 00:11:00.240 --> 00:11:05.240 ureteric obstruction, including ureteral stenosis 209 00:11:05.430 --> 00:11:09.690 and hydronephrosis occurred in patients receiving JELMYTO. 210 00:11:09.690 --> 00:11:12.090 Monitor patients for signs and symptoms 211 00:11:12.090 --> 00:11:16.140 of ureteric obstruction, including flank pain and fever, 212 00:11:16.140 --> 00:11:18.570 and for changes in renal function. 213 00:11:18.570 --> 00:11:20.550 Patients who experience obstruction 214 00:11:20.550 --> 00:11:23.970 may require transient or long term ureteral stents 215 00:11:23.970 --> 00:11:25.680 or alternative procedures. 216 00:11:25.680 --> 00:11:28.710 Withhold or permanently discontinued JELMYTO 217 00:11:28.710 --> 00:11:31.563 based on the severity of ureteric obstruction. 218 00:11:32.580 --> 00:11:34.260 Bone marrow suppression. 219 00:11:34.260 --> 00:11:37.740 The use of JELMYTO can result in bone marrow suppression, 220 00:11:37.740 --> 00:11:42.000 particularly thrombocytopenia and neutropenia. 221 00:11:42.000 --> 00:11:44.100 The following tests should be obtained 222 00:11:44.100 --> 00:11:45.990 prior to each treatment. 223 00:11:45.990 --> 00:11:48.570 Platelet count, white blood cell count 224 00:11:48.570 --> 00:11:50.493 differential and hemoglobin. 225 00:11:51.390 --> 00:11:52.560 Withhold JELMYTO 226 00:11:52.560 --> 00:11:56.490 for Grade 2 thrombocytopenia or neutropenia. 227 00:11:56.490 --> 00:11:57.690 Permanently discontinue 228 00:11:57.690 --> 00:12:01.893 for Grade 3 or greater thrombocytopenia or neutropenia. 229 00:12:03.480 --> 00:12:05.343 Embryo-fetal toxicity. 230 00:12:06.270 --> 00:12:09.780 Based on findings in animals and mechanism of action, 231 00:12:09.780 --> 00:12:11.760 JELMYTO can cause fetal harm 232 00:12:11.760 --> 00:12:14.280 when administered to a pregnant woman. 233 00:12:14.280 --> 00:12:16.590 In animal reproduction studies, 234 00:12:16.590 --> 00:12:20.403 administration of mitomycin resulted in teratogenicity. 235 00:12:21.810 --> 00:12:24.330 Advise females of reproductive potential 236 00:12:24.330 --> 00:12:26.340 to use effective contraception 237 00:12:26.340 --> 00:12:28.260 during treatment with JELMYTO 238 00:12:28.260 --> 00:12:30.993 and for six months following the last dose. 239 00:12:31.890 --> 00:12:34.350 Advise male patients with female partners 240 00:12:34.350 --> 00:12:36.090 of reproductive potential 241 00:12:36.090 --> 00:12:39.780 to use effective contraception during treatment with JELMYTO 242 00:12:39.780 --> 00:12:43.290 and for three months following the last dose. 243 00:12:43.290 --> 00:12:45.450 Common adverse reactions. 244 00:12:45.450 --> 00:12:47.430 The most common adverse reactions 245 00:12:47.430 --> 00:12:50.100 in greater than or equal to 20% of patients 246 00:12:50.100 --> 00:12:54.420 treated with JELMYTO were ureteric obstruction, flank pain, 247 00:12:54.420 --> 00:12:58.680 urinary tract infection, hematuria, abdominal pain, 248 00:12:58.680 --> 00:13:03.550 fatigue, renal dysfunction, nausea, dysuria, and vomiting 249 00:13:04.470 --> 00:13:07.140 Additional adverse reactions information. 250 00:13:07.140 --> 00:13:10.500 Selected clinically relevant adverse reactions 251 00:13:10.500 --> 00:13:15.270 in less than 10% and greater than or equal to 2% of patients 252 00:13:15.270 --> 00:13:19.530 who received JELMYTO include urinary tract inflammation, 253 00:13:19.530 --> 00:13:21.900 bladder spasm, urosepsis, 254 00:13:21.900 --> 00:13:25.143 hypersensitivity, and instillation site pain. 255 00:13:26.460 --> 00:13:28.830 Use in specific populations. 256 00:13:28.830 --> 00:13:30.090 Lactation. 257 00:13:30.090 --> 00:13:33.180 Because of the potential for serious adverse reactions 258 00:13:33.180 --> 00:13:35.370 in a breastfed child, 259 00:13:35.370 --> 00:13:39.000 advise women not to breastfeed during treatment with JELMYTO 260 00:13:39.000 --> 00:13:41.613 and for one week following the last dose. 261 00:13:42.450 --> 00:13:45.960 Preparation and administration information. 262 00:13:45.960 --> 00:13:49.140 JELMYTO is for pyelocalyceal use only 263 00:13:49.140 --> 00:13:52.170 and not for intravenous use, topical use, 264 00:13:52.170 --> 00:13:54.630 or oral administration. 265 00:13:54.630 --> 00:13:57.030 JELMYTO must be prepared and administered 266 00:13:57.030 --> 00:13:58.890 by a healthcare provider. 267 00:13:58.890 --> 00:14:00.390 To ensure proper dosing, 268 00:14:00.390 --> 00:14:03.270 it is important to follow the preparation instructions 269 00:14:03.270 --> 00:14:06.270 found in the JELMYTO Instructions for Pharmacy 270 00:14:06.270 --> 00:14:08.280 and administration instructions 271 00:14:08.280 --> 00:14:12.240 found in the JELMYTO Instructions for Administration. 272 00:14:12.240 --> 00:14:15.870 JELMYTO may discolor urine to a violet to blue color 273 00:14:15.870 --> 00:14:18.000 following the instillation procedure. 274 00:14:18.000 --> 00:14:20.640 Advise patients to avoid contact with urine 275 00:14:20.640 --> 00:14:24.240 for at least six hours post-instillation, 276 00:14:24.240 --> 00:14:26.580 to void urine sitting on a toilet, 277 00:14:26.580 --> 00:14:30.300 and to flush the toilet several times after use. 278 00:14:30.300 --> 00:14:32.370 JELMYTO is a hazardous drug. 279 00:14:32.370 --> 00:14:35.913 Follow applicable special handling and disposal procedures. 280 00:14:36.870 --> 00:14:39.930 Please see accompanying Full Prescribing Information, 281 00:14:39.930 --> 00:14:41.550 Instructions for Pharmacy, 282 00:14:41.550 --> 00:14:43.533 and Instructions for Administration. 283 00:14:45.840 --> 00:14:48.360 JELMYTO and UroGen are registered trademarks 284 00:14:48.360 --> 00:14:50.100 of UroGen Pharma Limited. 285 00:14:50.100 --> 00:14:51.660 All other trademarks are the property 286 00:14:51.660 --> 00:14:53.010 of their respective owners. 287 00:14:54.390 --> 00:14:58.983 Please visit JELMYTO.com/hcp for more information.